Enlitic Confirms Cloud-Scale Performance of Ensight Platform on Oracle Infrastructure.
Enlitic (ASX: ENL) has successfully completed a technical validation of its Ensight medical imaging data standardisation platform on Oracle Cloud Infrastructure, using AMD EPYC processors. The validation was designed to confirm that Ensight can operate reliably and consistently at scale within a modern cloud environment that supports diverse clinical, operational, and research use cases. Testing was conducted on anonymised medical imaging datasets representative of real-world healthcare settings and spanning multiple anatomical areas and clinical scenarios. The assessment evaluated system performance across different data volumes and infrastructure configurations, mirroring conditions faced by hospitals, radiology groups, and research organisations. Results confirmed accurate execution of imaging standardisation and normalisation processes, stable system behaviour comparable to prior infrastructure, and seamless integration with Oracle’s storage and managed database services. The successful validation provides healthcare customers with an additional, proven cloud deployment option, reinforcing Ensight’s suitability for secure, large-scale medical imaging workflows in enterprise-grade cloud environments.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Enlitic Confirms Cloud-Scale Performance of Ensight Platform on Oracle Infrastructure.
Enlitic (ASX: ENL) has successfully completed a technical validation of its Ensight medical imaging data standardisation platform on Oracle Cloud Infrastructure, using AMD EPYC processors. The validation was designed to confirm that Ensight can operate reliably and consistently at scale within a modern cloud environment that supports diverse clinical, operational, and research use cases. Testing was conducted on anonymised medical imaging datasets representative of real-world healthcare settings and spanning multiple anatomical areas and clinical scenarios. The assessment evaluated system performance across different data volumes and infrastructure configurations, mirroring conditions faced by hospitals, radiology groups, and research organisations. Results confirmed accurate execution of imaging standardisation and normalisation processes, stable system behaviour comparable to prior infrastructure, and seamless integration with Oracle’s storage and managed database services. The successful validation provides healthcare customers with an additional, proven cloud deployment option, reinforcing Ensight’s suitability for secure, large-scale medical imaging workflows in enterprise-grade cloud environments.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au